New cell therapy keeps four children alive years after terminal brain cancer diagnosis
Four children with terminal brain cancers remain alive years after receiving an experimental T-cell therapy targeting three common tumour markers.
Four children with terminal brain cancers remain alive years after receiving an experimental T-cell therapy targeting three common tumour markers.
Semaglutide reduced epigenetic ageing across multiple clocks including PhenoAge by 4.9 years per year and DunedinPACE by 0.09 units in a 32-week trial.